The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Factor VIII Deficiency Treatment-Global Market Insights and Sales Trends 2024
Synopsis
Factor VIII is an essential blood-clotting protein, which is also known as an antihemophilic factor. In individuals, factor VIII is encoded by F8 gene. Defects in F8 gene lead to hemophilia A, a recessive X-linked coagulation disorder. Factor VIII is generated in liver sinusoidal cells and endothelial cells outside the liver across the body. This protein mixes in the bloodstream in an inactive form, and binds to another molecule called von Willebrand factor, until a damage to blood vessels occur. In response to injury, coagulation factor VIII gets activated and separates from von Willebrand factor.
The global Factor VIII Deficiency Treatment market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Factor VIII Deficiency Treatment in various end use industries. The expanding demands from the Hospitals, Clinics and Other, are propelling Factor VIII Deficiency Treatment market. Hemophilia A Drugs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Hemophilia A Inhibitors Treatment segment is estimated at % CAGR for the next seven-year period.
The global hemophilia A drugs market segment accounted for the majority market share and will continue to dominate the factor 8 deficiency treatment market for the next few years. Some of the major factors responsible for the market segment's growth is the growing incidence of hemophilia A, the development of novel drugs with extended action, and the increased adoption of prophylactic treatment. Additionally, growing demand for novel recombinant extended half-life products, the emergence of monoclonal antibodies and gene therapy products, and launch of plasma-derived products for recombinant factor VIII at low costs, will also further drive the growth of the factor VIII deficiency treatment market.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Factor VIII Deficiency Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Factor VIII Deficiency Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Factor VIII Deficiency Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Factor VIII Deficiency Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Factor VIII Deficiency Treatment covered in this report include Pfizer, Takeda, Bayer HealthCare, CSL, Grifols, Novo Nordisk, F. Hoffmann-La Roche, Kedrion and Octapharma, etc.
The global Factor VIII Deficiency Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Takeda
Bayer HealthCare
CSL
Grifols
Novo Nordisk
F. Hoffmann-La Roche
Kedrion
Octapharma
Biogen Idec
BioMarin Pharmaceutical
Sangamo Therapeutics
Spark Therapeutics
Swedish Orphan Biovitrum
Uniqure NV
Amarna Therapeutics
Dimension Therapeutics
Global Factor VIII Deficiency Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Factor VIII Deficiency Treatment market, Segment by Type:
Hemophilia A Drugs
Hemophilia A Inhibitors Treatment
Von Willebrand Disease Treatment
Global Factor VIII Deficiency Treatment market, by Application
Hospitals
Clinics
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Factor VIII Deficiency Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Factor VIII is an essential blood-clotting protein, which is also known as an antihemophilic factor. In individuals, factor VIII is encoded by F8 gene. Defects in F8 gene lead to hemophilia A, a recessive X-linked coagulation disorder. Factor VIII is generated in liver sinusoidal cells and endothelial cells outside the liver across the body. This protein mixes in the bloodstream in an inactive form, and binds to another molecule called von Willebrand factor, until a damage to blood vessels occur. In response to injury, coagulation factor VIII gets activated and separates from von Willebrand factor.
The global Factor VIII Deficiency Treatment market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Factor VIII Deficiency Treatment in various end use industries. The expanding demands from the Hospitals, Clinics and Other, are propelling Factor VIII Deficiency Treatment market. Hemophilia A Drugs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Hemophilia A Inhibitors Treatment segment is estimated at % CAGR for the next seven-year period.
The global hemophilia A drugs market segment accounted for the majority market share and will continue to dominate the factor 8 deficiency treatment market for the next few years. Some of the major factors responsible for the market segment's growth is the growing incidence of hemophilia A, the development of novel drugs with extended action, and the increased adoption of prophylactic treatment. Additionally, growing demand for novel recombinant extended half-life products, the emergence of monoclonal antibodies and gene therapy products, and launch of plasma-derived products for recombinant factor VIII at low costs, will also further drive the growth of the factor VIII deficiency treatment market.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Factor VIII Deficiency Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Factor VIII Deficiency Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Factor VIII Deficiency Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Factor VIII Deficiency Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Factor VIII Deficiency Treatment covered in this report include Pfizer, Takeda, Bayer HealthCare, CSL, Grifols, Novo Nordisk, F. Hoffmann-La Roche, Kedrion and Octapharma, etc.
The global Factor VIII Deficiency Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Takeda
Bayer HealthCare
CSL
Grifols
Novo Nordisk
F. Hoffmann-La Roche
Kedrion
Octapharma
Biogen Idec
BioMarin Pharmaceutical
Sangamo Therapeutics
Spark Therapeutics
Swedish Orphan Biovitrum
Uniqure NV
Amarna Therapeutics
Dimension Therapeutics
Global Factor VIII Deficiency Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Factor VIII Deficiency Treatment market, Segment by Type:
Hemophilia A Drugs
Hemophilia A Inhibitors Treatment
Von Willebrand Disease Treatment
Global Factor VIII Deficiency Treatment market, by Application
Hospitals
Clinics
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Factor VIII Deficiency Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Factor VIII Deficiency Treatment
1.1 Factor VIII Deficiency Treatment Market Overview
1.1.1 Factor VIII Deficiency Treatment Product Scope
1.1.2 Factor VIII Deficiency Treatment Market Status and Outlook
1.2 Global Factor VIII Deficiency Treatment Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Factor VIII Deficiency Treatment Market Size by Region (2018-2029)
1.4 Global Factor VIII Deficiency Treatment Historic Market Size by Region (2018-2023)
1.5 Global Factor VIII Deficiency Treatment Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Factor VIII Deficiency Treatment Market Size (2018-2029)
1.6.1 North America Factor VIII Deficiency Treatment Market Size (2018-2029)
1.6.2 Europe Factor VIII Deficiency Treatment Market Size (2018-2029)
1.6.3 Asia-Pacific Factor VIII Deficiency Treatment Market Size (2018-2029)
1.6.4 Latin America Factor VIII Deficiency Treatment Market Size (2018-2029)
1.6.5 Middle East & Africa Factor VIII Deficiency Treatment Market Size (2018-2029)
2 Factor VIII Deficiency Treatment Market by Type
2.1 Introduction
2.1.1 Hemophilia A Drugs
2.1.2 Hemophilia A Inhibitors Treatment
2.1.3 Von Willebrand Disease Treatment
2.2 Global Factor VIII Deficiency Treatment Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Factor VIII Deficiency Treatment Historic Market Size by Type (2018-2023)
2.2.2 Global Factor VIII Deficiency Treatment Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Factor VIII Deficiency Treatment Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Factor VIII Deficiency Treatment Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Factor VIII Deficiency Treatment Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Factor VIII Deficiency Treatment Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Factor VIII Deficiency Treatment Revenue Breakdown by Type (2018-2029)
3 Factor VIII Deficiency Treatment Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Other
3.2 Global Factor VIII Deficiency Treatment Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Factor VIII Deficiency Treatment Historic Market Size by Application (2018-2023)
3.2.2 Global Factor VIII Deficiency Treatment Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Factor VIII Deficiency Treatment Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Factor VIII Deficiency Treatment Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Factor VIII Deficiency Treatment Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Factor VIII Deficiency Treatment Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Factor VIII Deficiency Treatment Revenue Breakdown by Application (2018-2029)
4 Factor VIII Deficiency Treatment Competition Analysis by Players
4.1 Global Factor VIII Deficiency Treatment Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Factor VIII Deficiency Treatment as of 2022)
4.3 Date of Key Players Enter into Factor VIII Deficiency Treatment Market
4.4 Global Top Players Factor VIII Deficiency Treatment Headquarters and Area Served
4.5 Key Players Factor VIII Deficiency Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Factor VIII Deficiency Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Pfizer
5.1.1 Pfizer Profile
5.1.2 Pfizer Main Business
5.1.3 Pfizer Factor VIII Deficiency Treatment Products, Services and Solutions
5.1.4 Pfizer Factor VIII Deficiency Treatment Revenue (US$ Million) & (2018-2023)
5.1.5 Pfizer Recent Developments
5.2 Takeda
5.2.1 Takeda Profile
5.2.2 Takeda Main Business
5.2.3 Takeda Factor VIII Deficiency Treatment Products, Services and Solutions
5.2.4 Takeda Factor VIII Deficiency Treatment Revenue (US$ Million) & (2018-2023)
5.2.5 Takeda Recent Developments
5.3 Bayer HealthCare
5.3.1 Bayer HealthCare Profile
5.3.2 Bayer HealthCare Main Business
5.3.3 Bayer HealthCare Factor VIII Deficiency Treatment Products, Services and Solutions
5.3.4 Bayer HealthCare Factor VIII Deficiency Treatment Revenue (US$ Million) & (2018-2023)
5.3.5 CSL Recent Developments
5.4 CSL
5.4.1 CSL Profile
5.4.2 CSL Main Business
5.4.3 CSL Factor VIII Deficiency Treatment Products, Services and Solutions
5.4.4 CSL Factor VIII Deficiency Treatment Revenue (US$ Million) & (2018-2023)
5.4.5 CSL Recent Developments
5.5 Grifols
5.5.1 Grifols Profile
5.5.2 Grifols Main Business
5.5.3 Grifols Factor VIII Deficiency Treatment Products, Services and Solutions
5.5.4 Grifols Factor VIII Deficiency Treatment Revenue (US$ Million) & (2018-2023)
5.5.5 Grifols Recent Developments
5.6 Novo Nordisk
5.6.1 Novo Nordisk Profile
5.6.2 Novo Nordisk Main Business
5.6.3 Novo Nordisk Factor VIII Deficiency Treatment Products, Services and Solutions
5.6.4 Novo Nordisk Factor VIII Deficiency Treatment Revenue (US$ Million) & (2018-2023)
5.6.5 Novo Nordisk Recent Developments
5.7 F. Hoffmann-La Roche
5.7.1 F. Hoffmann-La Roche Profile
5.7.2 F. Hoffmann-La Roche Main Business
5.7.3 F. Hoffmann-La Roche Factor VIII Deficiency Treatment Products, Services and Solutions
5.7.4 F. Hoffmann-La Roche Factor VIII Deficiency Treatment Revenue (US$ Million) & (2018-2023)
5.7.5 F. Hoffmann-La Roche Recent Developments
5.8 Kedrion
5.8.1 Kedrion Profile
5.8.2 Kedrion Main Business
5.8.3 Kedrion Factor VIII Deficiency Treatment Products, Services and Solutions
5.8.4 Kedrion Factor VIII Deficiency Treatment Revenue (US$ Million) & (2018-2023)
5.8.5 Kedrion Recent Developments
5.9 Octapharma
5.9.1 Octapharma Profile
5.9.2 Octapharma Main Business
5.9.3 Octapharma Factor VIII Deficiency Treatment Products, Services and Solutions
5.9.4 Octapharma Factor VIII Deficiency Treatment Revenue (US$ Million) & (2018-2023)
5.9.5 Octapharma Recent Developments
5.10 Biogen Idec
5.10.1 Biogen Idec Profile
5.10.2 Biogen Idec Main Business
5.10.3 Biogen Idec Factor VIII Deficiency Treatment Products, Services and Solutions
5.10.4 Biogen Idec Factor VIII Deficiency Treatment Revenue (US$ Million) & (2018-2023)
5.10.5 Biogen Idec Recent Developments
5.11 BioMarin Pharmaceutical
5.11.1 BioMarin Pharmaceutical Profile
5.11.2 BioMarin Pharmaceutical Main Business
5.11.3 BioMarin Pharmaceutical Factor VIII Deficiency Treatment Products, Services and Solutions
5.11.4 BioMarin Pharmaceutical Factor VIII Deficiency Treatment Revenue (US$ Million) & (2018-2023)
5.11.5 BioMarin Pharmaceutical Recent Developments
5.12 Sangamo Therapeutics
5.12.1 Sangamo Therapeutics Profile
5.12.2 Sangamo Therapeutics Main Business
5.12.3 Sangamo Therapeutics Factor VIII Deficiency Treatment Products, Services and Solutions
5.12.4 Sangamo Therapeutics Factor VIII Deficiency Treatment Revenue (US$ Million) & (2018-2023)
5.12.5 Sangamo Therapeutics Recent Developments
5.13 Spark Therapeutics
5.13.1 Spark Therapeutics Profile
5.13.2 Spark Therapeutics Main Business
5.13.3 Spark Therapeutics Factor VIII Deficiency Treatment Products, Services and Solutions
5.13.4 Spark Therapeutics Factor VIII Deficiency Treatment Revenue (US$ Million) & (2018-2023)
5.13.5 Spark Therapeutics Recent Developments
5.14 Swedish Orphan Biovitrum
5.14.1 Swedish Orphan Biovitrum Profile
5.14.2 Swedish Orphan Biovitrum Main Business
5.14.3 Swedish Orphan Biovitrum Factor VIII Deficiency Treatment Products, Services and Solutions
5.14.4 Swedish Orphan Biovitrum Factor VIII Deficiency Treatment Revenue (US$ Million) & (2018-2023)
5.14.5 Swedish Orphan Biovitrum Recent Developments
5.15 Uniqure NV
5.15.1 Uniqure NV Profile
5.15.2 Uniqure NV Main Business
5.15.3 Uniqure NV Factor VIII Deficiency Treatment Products, Services and Solutions
5.15.4 Uniqure NV Factor VIII Deficiency Treatment Revenue (US$ Million) & (2018-2023)
5.15.5 Uniqure NV Recent Developments
5.16 Amarna Therapeutics
5.16.1 Amarna Therapeutics Profile
5.16.2 Amarna Therapeutics Main Business
5.16.3 Amarna Therapeutics Factor VIII Deficiency Treatment Products, Services and Solutions
5.16.4 Amarna Therapeutics Factor VIII Deficiency Treatment Revenue (US$ Million) & (2018-2023)
5.16.5 Amarna Therapeutics Recent Developments
5.17 Dimension Therapeutics
5.17.1 Dimension Therapeutics Profile
5.17.2 Dimension Therapeutics Main Business
5.17.3 Dimension Therapeutics Factor VIII Deficiency Treatment Products, Services and Solutions
5.17.4 Dimension Therapeutics Factor VIII Deficiency Treatment Revenue (US$ Million) & (2018-2023)
5.17.5 Dimension Therapeutics Recent Developments
6 North America
6.1 North America Factor VIII Deficiency Treatment Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Factor VIII Deficiency Treatment Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Factor VIII Deficiency Treatment Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Factor VIII Deficiency Treatment Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Factor VIII Deficiency Treatment Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Factor VIII Deficiency Treatment Market Dynamics
11.1 Factor VIII Deficiency Treatment Industry Trends
11.2 Factor VIII Deficiency Treatment Market Drivers
11.3 Factor VIII Deficiency Treatment Market Challenges
11.4 Factor VIII Deficiency Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
